DK3420084T3 - Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser - Google Patents

Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser Download PDF

Info

Publication number
DK3420084T3
DK3420084T3 DK17706515.8T DK17706515T DK3420084T3 DK 3420084 T3 DK3420084 T3 DK 3420084T3 DK 17706515 T DK17706515 T DK 17706515T DK 3420084 T3 DK3420084 T3 DK 3420084T3
Authority
DK
Denmark
Prior art keywords
unpermanent
approach
treatment
inflammatory disorders
disorders
Prior art date
Application number
DK17706515.8T
Other languages
English (en)
Inventor
Frank Jaschinski
Ksenija Schirduan
Sven Michel
Original Assignee
Secarna Pharmaceuticals Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16000468.5A external-priority patent/EP3211081A1/en
Application filed by Secarna Pharmaceuticals Gmbh & Co Kg filed Critical Secarna Pharmaceuticals Gmbh & Co Kg
Application granted granted Critical
Publication of DK3420084T3 publication Critical patent/DK3420084T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17706515.8T 2016-02-26 2017-02-24 Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser DK3420084T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000468.5A EP3211081A1 (en) 2016-02-26 2016-02-26 Novel approach for treating inflammatory disorders
EP16002305 2016-10-27
PCT/EP2017/054374 WO2017144685A1 (en) 2016-02-26 2017-02-24 Novel approach for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
DK3420084T3 true DK3420084T3 (da) 2021-10-25

Family

ID=58098650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17706515.8T DK3420084T3 (da) 2016-02-26 2017-02-24 Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser

Country Status (6)

Country Link
US (1) US10647987B2 (da)
EP (1) EP3420084B1 (da)
JP (1) JP7065778B2 (da)
DK (1) DK3420084T3 (da)
ES (1) ES2895275T3 (da)
WO (1) WO2017144685A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440723A (zh) * 2020-03-04 2020-07-24 西北农林科技大学 刺激Th17细胞增殖活化的肠道微生物培养基及培养方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309406A (en) 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US20060101530A1 (en) 2002-09-16 2006-05-11 Helen Francis-Lang Rors as modifiers of the p21 pathway and methods of use
DE10346487A1 (de) 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
EP1771204A4 (en) 2004-07-01 2008-08-13 Univ New York COMPOSITIONS AND METHOD FOR MODULATING ROR-GAMMA-T
EP1924294A4 (en) * 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US9629910B2 (en) 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
CN102732562A (zh) 2012-06-27 2012-10-17 中国人民解放军第三军医大学 抑制cyp2c8基因表达的方法
CN105308182B (zh) 2013-03-27 2018-09-25 伊萨纳治疗有限公司 修饰的TGF-β2寡核苷酸

Also Published As

Publication number Publication date
JP2019506174A (ja) 2019-03-07
US20190055566A1 (en) 2019-02-21
JP7065778B2 (ja) 2022-05-12
EP3420084B1 (en) 2021-08-04
WO2017144685A1 (en) 2017-08-31
US10647987B2 (en) 2020-05-12
ES2895275T3 (es) 2022-02-18
EP3420084A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
DK3515937T3 (da) Behandling af refraktorisk migræne
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3269716T3 (da) Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser
DK3364993T3 (da) Fremgangsmåder til behandling af angelman syndrom
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3224269T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3261721T3 (da) Anvendelse af pridopidin til forbedring af hukommelse
DK3265085T3 (da) Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3261726T3 (da) Sammensætning til behandling af acne
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3548061T3 (da) Behandling af neurologiske sygdomme
DK3283210T3 (da) Fremgangsmåde
DK3132009T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
DK3848028T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation